Cell therapy

Nature

Volumn 392, Issue 6679 SUPPL., 1998, Pages 18-24

  Gage, Fred H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; AUTOGRAFT; AUTOTRANSPLANTATION; CELL LINEAGE; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; CELL LINEAGE; CELL PHYSIOLOGY; CELL TRANSPLANTATION; FORECASTING; HUMANS; LEGISLATION; PARKINSON DISEASE; TISSUE THERAPY; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032580350     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Chang, P. L. Somatic Gene Therapy (1995).
2. Verma, I. M. & Somia, N. Gene therapy: promises, problems and prospect. Nature 389, 239-242 (1997).
3. Blau, H. & Springer, M. Muscle-mediated gene therapy. N. Engl. J. Med. 333, 1554-1556 (1995).
4. Chick, W. L. et al. Artificial pancreas using living beta cells: effects on glucose homeostasis in diabetic rats. Science 197, 780-782 (1977).
5. Sullivan, S. J. et al. Biohybrid artificial pancreas: long-term implantation studies in diabetic, pancreatectomized dogs. Science 252, 718-721 (1991).
6. Soon-Shiong, P. et al. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet 343, 950-951 (1994).
7. Soon-Shiong, P. et al. Long-term reversal of diabetes by the injection of immunoprotected islets. Proc. Natl Acad. Sci. USA 90, 5843-5847 (1993).
8. Palmer, T. D., Thompson, A. R. & Miller, A. D. Production of human factor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophilia B. Blood 73, 438-445 (1989).
9. Dai, Y., Roman, M., Naviaux, R. K. & Verma, I. M. Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc. Natl Acad. Sci. USA 89, 10892-10895 (1992).
10. Yao, S. N., Smith, K. J. & Kurachi, K. Primary myoblast-mediated gene transfer persistent expression of human factor IX in mice. Gene Ther. 1, 99-107 (1994).
11. Grill, R., Murai, K., Blesch, A., Gage, F. H. & Tuszynski, M. H. Cellular delivery of neurotrophin-3 promotes corticospinal axonal growth and partial functional recovery after spinal cord injury. J. Neurosci. 17, 5560-5572 (1997).
12. Chen, K. S. & Gage, F. H. Somatic gene transfer of NGF to the aged brain: behavioral and morphological amelioration. J. Neurosci. 14, 2819-2825 (1995).
13. Winkler, J., Suhr, S. T., Gage, F. H., Thai, L. J. & Fisher, L. J. Essential role of neocortical acetylcholine in spatial memory. Nature 375, 484-487 (1995).
14. Emerich, D. F. et al. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 27, 395-399 (1997).
15. Naffakh, N. et al. Long-term secretion of therapeutic proteins from genetically modified skeletal muscles. Human Gene Ther. 7, 11-21 (1996).
16. Taylor, R. M. & Wolfe, J. M. Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase. Nature Med. 3, 771-774 (1997).
17. Gussoni, E. et al. Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Nature 356, 435-438 (1992).
18. Miller, R. G. et al. Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study. Muscle Nerve 4, 469-478 (1997).
19. Gouras, P. & Algvere, P. Retinal cell transplantation in the macula: new techniques. Vision Res. 36, 4121-4125 (1996).
20. Algvere, P. V. & Berglin, L. Transplantation of RPE in age-related macular degeneration: observations in disciform lesions and dry RPE atrophy. Gracles Arch. Clin. Exp. Ophthalmol. 235, 149-158 (1997).
21. Kaplan, H. J., Tezel, T. H., Berger, A. S., Wolf, M. L. & Del Priore, L. V. Human photoreceptor transplantation in retinitis pigmentosa: a safety study. Arch. Ophthalmol. 115, 1168-1172 (1997).
22. Falci, S. et al. Obliteration of a posttraumatic spinal cord cryst with solid human embryonic spinal cord grafts: first clinical attempt. J. Neurotrauma 14, 875-884 (1997).
23. Olanow, C. W., Kordower, J. H. & Freeman, T. B. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci. 19, 102-109 (1996).
24. Thorgeirsson, S. S. Hepatic stem cells in liver regeneration. FASEB J. 10, 1249-1256 (1996).
25. Michalopoulos, G. K. & Defrances, M. C. Liver regeneration. Science 276, 60-68 (1997).
26. Horwich, A. L. Inherited hepatic enzyme defects as candidates for liver-directed gene therapy. Curr. Top. Microbiol. Immunol. 168, 185-200 (1991).
27. Overturf, K. et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nature Genet. 12, 266-273 (1996).
28. Rhim, J. A. et al. Replacement of diseased mouse liver by hepatic cell transplantation. Science 263, 1149-1152 (1994).
29. Overturf, K. M. et al. Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes. Am. J. Pathol. 151, 1078-1097 (1997).
30. Sheridan, W. et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet i, 640-644 (1992).
31. Gribbin, J. C. et al. Immunologic purging of marrow assessed by PCR with autologous bone marrow transplantation for B-cell lymphoma. N. Engl. J. Med. 325, 1525-1533 (1991).
32. Uchida, N., Aguila, H. L., Fleming, W. H., Jerabek, L. & Weissman, I. L. Rapid and sustained hematopoietic recovery in lethally irradiated mice transplanted with purified Thy-1.1lo Lin-Sca-1+ hematopoietic stem cells. Blood 83, 3758-3778 (1994).
33. Anasetti, C., Martin, P. J., Storb, R. & Hansen, J. A. Engraftment of allogeneic hemopoietic stem cells in patients conditioned only with anti-CD3 monoclonal antibody BC3 plus methylprednisone. Blood 84, 249a (1994).
34. Broxmeyer, H. L. et al. Umbilical cord blood hematopoietic stem and repopulating cells in human clinical transplantation. Blood Cells 17, 313 (1991).
35. Shpall, E. J., Jones, R. B. & Bearman, S. I. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. Curr. Sci. 6, 135-138 (1994).
36. Shpall, E. J. et al. High-dose therapy with autologous bone marrow transplantation for the treatment of solid tumors. J. Clin. Oncol. 12, 28-36 (1994).
37. Peters, W. P. et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J. Clin. Oncol. 11, 1132-1143 (1993).
38. Bhatia, M., Wang, J. C. Y., Kapp, U., Bonnet, D. & Dick, J. E. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc. Natl Acad. Sci. USA 94, 5320-5325 (1997).
39. Gallico, G. G. et al. Permanent coverage of large burn wounds with autologous cultured human epithelium. N. Engl. J. Med. 311, 448-551 (1984).
40. Rheinwald, J. G. & Green, H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 6, 331-344 (1975).
41. Brittberg, M. et al. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N. Engl. J. Med. 331, 884-895 (1994).
42. Boon, T. Antigenic tumor cell variants obtained with mutagens. Adv. Cancer Res. 39, 121-151 (1983).
43. Rosenberg, S. A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N. Engl. J. Med. 319, 1676-1680 (1988).
44. Pardol, D. M. Cancer vaccines. Immun. Today 14, 310 (1993).
45. Townsend, S. & Allison, J. P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259, 367-370 (1993).
46. Hohlfeld, R., Engel, A. G., Goebels, N. & Behrens, L. Cellular immune mechanisms in inflammatory myopathies. Curr. Opin. Rheumatol. 6, 520-526 (1997).
47. Cuono, C., Langdon, R. & McGuire, J. Use of cultured epidermal autografts and dermal allografts as skin replacement after bum injury. Lancet i, 1123-1124 (1986).
48. Yannas, I. V., Burke, J. F., Orgill, D. P. & Skrabut, E. M. Wound tissue can utilize a polymeric template to synthesize a functional extension of skin. Science 215, 174-176 (1982).
49. Rheinwald, J. G. in Cell Growth and Division: A Practical Approach (ed. Baserga, R.) 81-94 (Oxford Univ. Press, New York, 1989).
50. Bell, E., Ivarsson, B. & Merril, C. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc. Natl Acad. Sci. USA 76, 1274-1278 (1979).
51. Hansbrough, J. F., Morgan, J. & Greenleaf, G. Advances in, wound coverage using cultured cell technology. Wounds 5, 174-194 (1993).
52. Hansbrough, J. F. et al. Evaluation of a biodegradable matrix containing cultured human fibroblasts as a dermal replacement beneath meshed skin grafts on athymic mice. Surgery 4, 438-446 (1992).
53. Naughton, G., Mansbridge, J. & Gentzkow, G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif. Organs 21, 11 (1997).
54. Cepko, C. L. Immortalization of neuronal cells via retrovirus-mediated oncogene transduction. Annu. Rev. Neurosci 12, 47 (1937).
55. Martinez-Serrano, A. & Bjorklund, A. Immortalized neural progenitor cells for CNS gene transfer and repair. Trends Neurosci. 20, 530-538 (1997).
56. Hay, R. J. Human cells and cell cultures: availability, authentication and future prospects. Hum. Cell 9, 143-152 (1996).
57. Gossen, M. & Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl Acad. Sci. USA 89, 5547-5551 (1992).
58. Gossen, M. et al. Transcriptional activation by tetracyclines in mammalian cells. Science 23, 268 (1995).
59. Hoshimaru, M., Ray, J., Sah, D. W. Y. & Gage, F. H. Differentiation of the immortalized adult neuronal progenitor cell line HC2S2 into neurons by regulatable suppression of the v-myc oncogene. Proc. Natl Acad Sci. USA 93, 1518-1523 (1996).
60. Sah, D. W. Y., Ray, J. & Gage, F. H. Bipotent progenitor cell lines from the human CNS. Nature Biotech. 15, 574-580 (1997).
61. Kuhn, R., Schwenk, F., Aguet, M. & Rajewsky, K. Inducible gene targeting in mice. Science 269, 1427-1429 (1995).
62. Gu, H., Marth, J. D., Orban, P. C., Mossmann, H. & Rajewsky, K. Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. Science 265, 103-106 (1994).
63. Sauer, B. & Henderson, N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage Pl. Proc. Natl Acad. Sci. USA 85, 5166-5170 (1988).
64. Sternberg, N. & Hamilton, D. Bacteriophage Pl site-specific recombination. I. Recombination between loxP sites. J. Mol. Biol. 150, 467-486 (1981).
65. Schilling, A. et al. Dominant role of complement in the hyperacute xenograft rejection reaction. Surg. Obstet. 142, 29-32 (1976).
66. Pober, J. S. et al. Lymphocytes recognize human vascular endothelial and dermal fibroblast Ia antigens induced by recombinant immune interferon. Nature 205, 726-729 (1993).
67. Geppert, T. D. & Lipsky, P. E. Antigen presentation by interferon-gamma-treated endothelial cells and fibroblasts: differential ability to function as antigen-presenting cells despite comparable Ia expression. J. Immunol. 135, 3750-3762 (1985).
68. Gaspari, A. A. & Kalz, S. I. Induction and functional characterization of class II MHC (Ia) antigens on murine keratinocytes. J. Immunol. 140, 2956-2963 (1988).
69. Fisher, L. J. & Gage, F. H. Grafting in the mammalian central nervous system. Physiol. Rev. 73, 583-616 (1993).
70. Borlongan, C. V. et al. CNS immunological modulation of neural graft rejection and survival. Neurol. Res. 4, 297-304 (1996).
71. Scharp, D. W. et al. Protection of encapsulated human islets implanted without immunosuppression in patients with type I or type II diabetes and in nondiabetic control subjects. Diabetes 43, 1167-1170 (1994).
72. Joseph, J. M. et al. Transplantation of encapsulated bovine chromaffin cells in the sheep subarachnoid space: a preclinical study for treatment of cancer pain. Cell Transplant 3, 355-364 (1994).
73. Aebischer, P. et al. A bioartificial parathyroid. Trans. Am. Soc. Artif. Intern. Organs 32, 134-137 (1986).
74. Lacy, P. E. & Kostianovsky, M. A. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16, 35 (1967).
75. Ricordi, C., Lacy, P. E., Finke, E. H., Olack, B. J. & Scharp, D. W. Automated method for isolation of human pancreatic Islets. Diabetes 37, 413 (1988).
76. Thomas, F. H. Pancreas islet transplantation. Curr. Surg. 343-353 (1991).
77. Thomas, F. T. et al. Comparative efficacy of immunosuppressive drugs in xenografting. Transplant. Proc. 22, 1083-1085 (1990).
78. Hartner, W. C. et al. Specific tolerance to canine renal allografts following treatment with fractured bone marrow and antilymphocyte serum. Transplant. Proc. 19, 476-477 (1994).
79. Sabatini, D. M., Lai, M. M. & Snyder, S. H. Neural roles of immunophilins and their ligands. Mol. Neurobiol. 2, 223-239 (1997).
80. Thomas, J. M., Berbanac, K. M. & Thomas, F. T. The veto mechanism in transplant tolerance. Transpl. Rev. 5, 209-229 (1991).
81. US Food and Drug Adminstration Points to Consider in the Characterization of Cells Used to Produce Biologicals (US Department of Health and Human Services, Bethedsda, MD, 1993).
82. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy. J. Biol. Stand. 17, 213 (1989).
83. Koller, W. et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Tremor Ann. Neurol. 42, 292-299 (1997).
84. Baron, M. S. et al. Treatment of advanced Parkinson's disease by posterior Gpi pallidotomy: 1-year results of a pilot study. Ann. Neurol. 40, 355-366 (1996).
85. Olanow, C.W. et al. Autologous transplantation of adrenal medulla in Parkinson's disease: 18-month results. Arch Neurol. 47, 1286-1289 (1990).
86. Lindvall, O. et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann. Neurol. 35, 172-180 (1994).
87. Kordower, J. J. et al. Neuropathological evidence of graft survival and striatal reinnervations after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med. 2717, 1118-1124 (1997).
88. Gage, F. H. Parkinson's disease: fetal implants put to the test. Nature 361, 405-406 (1993).
89. Takayama, H. et al. Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease. Nature Med. 1, 53-58 (1995).
90. Gage, F. H., Ray, J. & Fisher, L. J. Isolation, characterization, and use of stem cells from the CNS. Annu. Rev. Neurosci. 18, 159-192 (1995).
91. Morrison, S. J., Nirao, M. S. & Anderson, D. J. Regulatory mechanisms in stem cell biology. Cell 88, 287-293 (1997).
92. McKay, R. Stem cells in the central nervous system. Science 276, 66-71 (1997).
93. Sussman, N. L. et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 16, 60-65 (1992).
94. Magometschnigg, H. et al. Prospective clinical study with in vitro endothelial cell lining of expanded polytetrafluoroethylene grafts in crural repeat reconstruction. J. Vasc. Surg. 15, 537 (1992).